CLN.WAR Celon Pharma SA

Healthcare Pharmaceuticals Warsaw Stock Exchange
16.86 PLN
Close of Oct 29, 2026
16.86 23.50
Market cap
PLN 909M
P/E
8.0x
P/B
1.90x
ROE
53.0%
Dividend yield
-
Fundamental score
2.0/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is CLN.WAR undervalued?

Graham number
Price16.86
Graham value20.60
Discount18.1%

CLN.WAR trades 18.1% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Celon Pharma SA fundamental analysis

8 of 22 checks passed

ROE 2/2

High return on equity (53.0%), above 20%.

ROA 1/1

Return on assets (36.0%) is above the industry median (3.8%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share did not grow over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-124.7%) is below the industry median (14.7%).

Revenue Growth 2/2

Revenue grew 14.7% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 0/1

Current assets do not cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (25.8%), 40% or less.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Operating cash flow does not cover 20% of total debt.

Interest Coverage 0/1

EBIT is negative, against interest expense, below 5x.

PE vs Market 1/1

PE (8.3x) is below the market median (11.6x).

PE vs Industry 1/1

PE (8.3x) is below the industry median (16.6x).

PBV 0/1

Price to book (2.0x) is above the industry median (1.5x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 16.4, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Celon Pharma SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Celon Pharma SA

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. Celon Pharma S.A. was founded in 2002 and is based in Lomianki, Poland. The company operates as a subsidiary of Glatton Sp. z o.o.

Full company profile